Literature DB >> 17699166

ACE inhibitors: back to prime time?

Milan Gupta, Subodh Verma, G B John Mancini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17699166      PMCID： PMC1955013          DOI： 10.1136/hrt.2006.108100

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  21 in total

1.  Pharmacoeconomic analyses: making them transparent, making them credible.

Authors:  D Rennie; H S Luft
Journal:  JAMA       Date:  2000-04-26       Impact factor: 56.272

2.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

3.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

4.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

5.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

6.  Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.

Authors:  Andrew Briggs; Borislava Mihaylova; Mark Sculpher; Alistair Hall; Jane Wolstenholme; Maarten Simoons; Jaap Deckers; Roberto Ferrari; Willem J Remme; Michel Bertrand; Kim Fox
Journal:  Heart       Date:  2006-11-29       Impact factor: 5.994

7.  The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.

Authors:  B Pitt; B O'Neill; R Feldman; R Ferrari; L Schwartz; H Mudra; T Bass; C Pepine; M Texter; H Haber; A Uprichard; L Cashin-Hemphill; R S Lees
Journal:  Am J Cardiol       Date:  2001-05-01       Impact factor: 2.778

8.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Authors:  S Yusuf; C J Pepine; C Garces; H Pouleur; D Salem; J Kostis; C Benedict; M Rousseau; M Bourassa; B Pitt
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

9.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

10.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.